• Eric J Lehrer, William G Breen, Raj Singh, Joshua D Palmer, Paul D Brown, Daniel M Trifiletti, and Jason P Sheehan.
• Department of Radiation Oncology, Mayo Clinic, Rochester , Minnesota , USA.
• Neurosurgery. 2024 Aug 1; 95 (2): 253258253-258.

AbstractStereotactic radiosurgery (SRS) is an important weapon in the management of brain metastases. Single-fraction SRS is associated with local control rates ranging from approximately 70% to 100%, which are largely dependent on lesion and postoperative cavity size. The rates of local control and improved neurocognitive outcomes compared with conventional whole-brain radiation therapy have led to increased adoption of SRS in these settings. However, when treating larger targets and/or targets located in eloquent locations, the risk of normal tissue toxicity and adverse radiation effects within healthy brain tissue becomes significantly higher. Thus, hypofractionated SRS has become a widely adopted approach, which allows for the delivery of ablative doses of radiation while also minimizing the risk of toxicity. This approach has been studied in multiple retrospective reports in both the postoperative and intact settings. While there are no reported randomized data to date, there are trials underway evaluating this paradigm. In this article, we review the role of hypofractionated SRS in the management of brain metastases and emerging data that will serve to validate this treatment approach. Pertinent articles and references were obtained from a comprehensive search of PubMed/MEDLINE and clinicaltrials.gov .Copyright © Congress of Neurological Surgeons 2024. All rights reserved.

23 keywords...

hide…